March 24th, 2026 – SAN CARLOS, CA — Sift Biosciences is proud to announce that Dr. Yue Clare Lou, Co-Founder and CEO of Sift Biosciences, has been named to the Class of 2026 Termeer Fellows by the Termeer Institute. The cohort welcomes 17 first-time CEOs leading early-stage life sciences companies across four U.S. states and five countries.
“Proud to be named to the Class of 2026 Termeer Fellows!” said Dr. Lou. “Bringing therapy to patients demands excellence across every dimension: science, strategy, storytelling, and execution. Keeping patients at the center of our work at Sift Biosciences means constantly pushing myself to grow as a leader. The Termeer Institute Fellowship offers exactly that: executive coaching, an extensive network of experienced drug developers, and a community of founders and CEOs who share a deep commitment to patients and long-term impact.”
“As we advance our lead oncology program toward the clinic, I look forward to learning from and growing alongside this exceptional group. Thank you to the Termeer Institute for the opportunity!”
The Termeer Fellows program supports first-time CEOs through skill competency growth programming, executive coaching, mentoring, and network-building opportunities. Fellows across the program’s history have collectively raised $3.45 billion in funding, with 73% remaining in their roles as CEOs and 87% of their companies continuing to advance.
Read the full Termeer Institute announcement here.
About Sift Biosciences
Sift Biosciences is a preclinical immunotherapy company developing “T-cell booster” peptides designed to amplify immune responses in cancers and other immune diseases where current therapies fail. Founded in 2024 as a UC Berkeley spin-out, Sift combines AI, metagenomics, and high-throughput immune profiling to identify peptides capable of harnessing pre-existing immune memory for faster, safer, and more effective treatments. The company’s initial focus is on gastrointestinal and gynecologic cancers, with an expanding pipeline in autoimmunity.